Racial and ethnic differences in pharmacotherapy to prevent coronary artery disease and thrombotic events.

In patients with CYP2C19 LoF allele carriers enrolled in the TAILOR-PCI trial, the genotype-guided strategy (85% of this group received ticagrelor) compared with conventional therapy (99% clopidogrel) numerically reduced major cardiovascular events, but did not reach statistical significance (HR 0.66; 95% CI 0.43–1.02; P = 0.06). 27 A whole population of this trial included 23% of East Asian patients.

also in 111,027 other papers